Inventor
GUPTA ASHOK K
US35 patents
⚠️ This page may combine multiple inventors who share the name “GUPTA ASHOK K”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BRISTOL MYERS SQUIBB CO
18 patentsUS10072082B2Sep 11, 2018
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO58 citations99
US10604575B2Mar 31, 2020
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO26 citations98
US10584170B2Mar 10, 2020
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO23 citations98
US10577423B2Mar 3, 2020
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO23 citations98
US10323092B2Jun 18, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO30 citations98
US10323093B2Jun 18, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO29 citations98
US10316090B2Jun 11, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO29 citations98
US10316091B2Jun 11, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO30 citations98
US10308714B2Jun 4, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO30 citations98
US10266594B1Apr 23, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO29 citations98
US10266595B2Apr 23, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO28 citations98
US10266596B1Apr 23, 2019
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO29 citations98
US10138299B2Nov 27, 2018
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO39 citations98
US9212224B2Dec 15, 2015
Antibodies that bind PD-L1 and uses thereof
BRISTOL MYERS SQUIBB CO135 citations97
US9789182B2Oct 17, 2017
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
BRISTOL MYERS SQUIBB CO11 citations81
US12590154B2Mar 31, 2026
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
BRISTOL MYERS SQUIBB CO0 citations73
US10688180B2Jun 23, 2020
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
BRISTOL MYERS SQUIBB CO2 citations70
US10494433B2Dec 3, 2019
Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
BRISTOL MYERS SQUIBB CO1 citations56
KERNFORSCHUNGSANLAGE JUELICH
7 patentsUS4564496AJan 14, 1986
Method of making porous silicon carbide bodies
KERNFORSCHUNGSANLAGE JUELICH35 citations91
US4265843AMay 5, 1981
Method of producing shaped silicon-carbide bodies
KERNFORSCHUNGSANLAGE JUELICH39 citations87
US4526649AJul 2, 1985
Method of molding bonded parts with silicon carbide surfaces
KERNFORSCHUNGSANLAGE JUELICH21 citations81
US4487644ADec 11, 1984
Binderless weld-bonding of preshaped sic-base parts into solid bodies
KERNFORSCHUNGSANLAGE JUELICH23 citations80
US4722762AFeb 2, 1988
Method of making shaped bodies of silicon carbide or of graphite or graphite-like material with a silicon carbide surface
KERNFORSCHUNGSANLAGE JUELICH15 citations72
US4262039AApr 14, 1981
Pyrolytic gas method of coating graphitic or ceramic articles with solids
KERNFORSCHUNGSANLAGE JUELICH18 citations69
US4432957AFeb 21, 1984
Method of producing silicon carbide bodies
KERNFORSCHUNGSANLAGE JUELICH6 citations61
ABBOTT LAB
3 patentsUS6822101B2Nov 23, 2004
Process for preparing amine-substituted benzofurans
ABBOTT LAB2 citations61
US6710185B2Mar 23, 2004
Process for the preparation of cell proliferation inhibitors
ABBOTT LAB2 citations61
US5883236AMar 16, 1999
Process for N-desmethylating erythromycins and derivatives thereof
ABBOTT LAB5 citations58